Abstracts Archive - Page 923 of 2425 - ACR Meeting Abstracts

Abstract Number: 2470 • 2019 ACR/ARP Annual Meeting
Relationship Between Serum Calprotectin Level and Presence of Subclinical Atherosclerosis and Arterial Stiffness in Patient with Psoriatic Arthritis
Isaac T. Cheng¹, Martin M Li ¹, Edmund K Li ¹, Alex P Lee ¹ and Lai-Shan Tam ¹, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Calprotectin is a member of S100 leukocyte. Serum calprotectin is a sensitive biomarker of disease activity in patients with psoriatic arthritis (PsA). While various…
Abstract Number: 2471 • 2019 ACR/ARP Annual Meeting
Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study
Erkan Kilic¹, Gamze Kilic ², Kemal Nas ³, Betul Sargin ⁴, Sevtap Acer Kasman ⁵, Hakan Alkan ⁶, Nilay Sahin ⁷, Gizem Cengiz ⁸, Nihan Cuzdan ⁹, Ilknur Albayrak Gezer ¹⁰, Dilek Keskin ¹¹, Cevriye Mulkoglu ¹², Hatice Resorlu ¹³, Ismihan Sunar ¹⁴, Ajda Bal ¹⁵, Mehmet Tuncay Duruoz ⁵, Okan Kucukakkas ¹⁶, Ozan Volkan Yurdakul ¹⁶, Meltem Alkan Melikoglu ¹⁷, Yildiray Aydin ³, Fikriye Figen Ayhan ¹⁸, Hatice Bodur ¹⁹, Mustafa Calis ⁸, Erhan Capkin ²⁰, Gul Devrimsel ²¹, Kevser Gök ²², Sami Hizmetli ²³, Ayhan Kamanli ³, Yasar Keskin ¹⁶, Hilal Kocabas ²⁴, Oznur Kutluk ²⁵, Nesrin Sen ²⁶, Omer Faruk Sendur ²⁷, Ibrahim Tekeoglu ³, Sena Tolu ²⁸, Murat Toprak ²⁹ and Tiraje Tuncer ²⁵, ¹Afyonkarahisar State Hospital, Afyonkarahisar, Turkey, ²Karadeniz Technical University School of Medicine, Department of Physical Medicine and Rehabilitation, Trabzon, ³Sakarya University School of Medicine, PMR Department, Rheumatology and Immunology Division, Sakarya, Turkey, ⁴Adnan Menderes University School of Medicine, PMR Department, Rheumatology Division, Aydın, Turkey, ⁵Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ⁶Pamukkale University School of Medicine, PMR Department, Rheumatology Division, Denizli, Turkey, ⁷Balıkesir University School of Medicine, PMR Department, Balıkesir, Turkey, ⁸Erciyes University School of Medicine, PMR Department, Rheumatology Division, Kayseri, Turkey, ⁹Şanlıurfa Training and Research Hospital, Rheumatology Clinic, Şanlıurfa, Turkey, ¹⁰Selçuk University School of Medicine, PMR Department, Konya, Turkey, ¹¹Kırıkkale University School of Medicine, PMR Department, Kırıkkale, Turkey, ¹²Ankara Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹³Çanakkale Onsekiz Mart University School of Medicine, PMR Department, Çanakkale, Turkey, ¹⁴Ankara Unversity School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Turkey, ¹⁵Dışkapı Yıldırım Beyazıt Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹⁶Bezmialem Vakıf University School of Medicine, PMR Department, İstanbul, Turkey, ¹⁷Atatürk University School of Medicine, PMR Department, Rheumatology Division, Erzurum, Turkey, ¹⁸Uşak University School of Health Sciences, PMR Department, Uşak, Turkey, ¹⁹Yıldırım Beyazıt University School of Medicine, PMR Department, Ankara, Turkey, ²⁰Karadeniz Teknik University School of Medicine, PMR Department, Trabzon, Turkey, ²¹Recep Tayyip Erdoğan University School of Medicine, PMR Department, Riza, Turkey, ²²Numune Training and Research Hospital, Rheumatology Clinic, Ankara, Turkey, ²³Cumhuriyet University School of Medicine, PMR Department, Rheumatology Division, Sivas, Turkey, ²⁴Necmettin Erbakan University Meram School of Medicine, PMR Department, Rheumatology Division, Konya, Turkey, ²⁵Akdeniz University School of Medicine, PMR Department, Rheumatology Division, Antalya, Turkey, ²⁶Kartal Dr. Lütfi Kırdar Training and Research Hospital, Rheumatology Clinic, İstanbul, Turkey, ²⁷Adnan Menderes University School of Medicine, PMR Department, Aydın, Turkey, ²⁸Medipol University School of Medicine, PMR Department, İstanbul, Turkey, ²⁹Yüzüncü Yıl University School of Medicine, PMR Department, Van, Turkey
Background/Purpose: Psoriatic arthritis (PsA) has been defined as an inflammatory arthritis associated with psoriasis. The disease activity can be evaluated using many scales in patients…
Abstract Number: 2472 • 2019 ACR/ARP Annual Meeting
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis
Ari Polachek¹, Victoria Furer ², Mirna Zureik ², Sharon Nevo ², Liran Mendel ², David Levartovsky ³, Jonathan Wollman ⁴, Valerie Aloush ⁵, Mark Berman ⁶, Ilana Kaufman ⁶, Yael Lahat ², Hagit Sarbagil-Maman ⁷, Sara Borok ⁶, Adi Broyde ⁶, Lihi Eder ⁸, Daphna Paran ¹ and Ori Elkayam ⁹, ¹Tel-Aviv Sourasky medical center, Tel Aviv, Israel, ²Sourasky Medical Center, Tel-Aviv, Israel, ³Sourasky medical center, Tel Aviv, Israel, ⁴Sourasky Medical Center, Herzelia, Israel, ⁵Tel Aviv Sourasky medical center, Tel Aviv, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Tel-Aviv Sourasky medical center, Qiryat-Ono, Israel, ⁸Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁹Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis is a chronic inflammatory disease. More than 20% of patients with PsA patients suffer from fibromyalgia, a chronic pain syndrome characterized by…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 2474 • 2019 ACR/ARP Annual Meeting
Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Peter Hur ², Mei Liu ³, Sabrina Rebello ³, Robert McLean ³, Blessing Dube ³, Meghan Glynn ⁴ and Philip Mease ⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous presentations that may involve peripheral arthritis, axial disease, enthesitis, dactylitis, and psoriatic skin and…
Abstract Number: 2475 • 2019 ACR/ARP Annual Meeting
Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Peter Hur ², Mei Liu ³, Sabrina Rebello ³, Robert McLean ³, Blessing Dube ³, Meghan Glynn ⁴ and Philip Mease ⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease of the skin and musculoskeletal system. Six key domains of PsA have been identified to…
Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie¹, Ervant Maksabedian ², Bradley Stolshek ², Yomei Shaw ³ and Kaleb Michaud ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…
Abstract Number: 2477 • 2019 ACR/ARP Annual Meeting
Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu ², Meghan Glynn ³, Kelechi Emeanuru ², Leslie Harrold ⁴, Sven Richter ⁵, Benoit Guerette ⁵ and Philip Mease ⁶, ¹Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁵Celgene Corporation, Summit, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry,…
Abstract Number: 2478 • 2019 ACR/ARP Annual Meeting
Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan
Daniel Aletaha¹, Patrick Zueger ², Naijun Chen ² and Nicola Booth ³, ¹Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Enthesitis, a symptom commonly associated with psoriatic arthritis (PsA), negatively affects quality of life. Although enthesitis is routinely reported in randomized clinical trials of…
Abstract Number: 2479 • 2019 ACR/ARP Annual Meeting
Unmet Treatment Needs in Patients with Psoriatic Arthritis
Daniel Aletaha¹, Mihalina Georgallis ², Matthew Wallace ², Patrick Zueger ³ and Ruth Zeidman ², ¹Medical University of Vienna, Vienna, Austria, ²Covance Market Access & Phase IV Solutions, London, United Kingdom, ³AbbVie Inc., North Chicago
Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current…
Abstract Number: 2480 • 2019 ACR/ARP Annual Meeting
Opioid Use Surrounding Diagnosis of Inflammatory Arthritis
Anna Sheahan¹, Victor Sloan ¹, Jeffrey Stark ² and Robert Suruki ¹, ¹UCB Pharma, Raleigh, NC, ²UCB Pharma, Smyrna, GA
Background/Purpose: Although treatment of inflammatory arthritis (IA) has improved, opioid use among patients remains common. A study from Finland showed increases in opioid use leading…
Abstract Number: 2481 • 2019 ACR/ARP Annual Meeting
Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center
Iñigo Gonzalez-Mazon¹, Lara Sanchez-Bilbao ², Natalia Palmou-Fontana ¹, DAVID MARTINEZ-LOPEZ ³, Mónica Calderón-Goercke ⁴, DIANA PRIETO- PENA ¹, Susana Armesto-Alonso ³, Miguel A Gonzalez-Gay ² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Uveitis is an extra articular manifestation of psoriatic arthritis (PsA). Uveitis may be more chronic Biological therapy, especially monoclonal TNF inhibitors, are useful to…
Abstract Number: 2482 • 2019 ACR/ARP Annual Meeting
Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy
Diego Benavent¹, Chamaida Plasencia ², Victoria Navarro-Compán ³, Laura Nuño ⁴, Irene Monjo ⁵, Carolina Tornero ⁶ and Alejandro Balsa ⁷, ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁵FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ⁶Rheumatology Department. La Paz University Hospital., Madrid, ⁷Hospital Universitario La Paz, Madrid
Background/Purpose: Growing evidence has pointed gender as a key variable influencing clinical response to biological drugs in psoriatic arthritis(PsA). Although the reasons remain unclear, it…
Abstract Number: 2483 • 2019 ACR/ARP Annual Meeting
Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia ², Victoria Navarro-Compán ³, Diana Peiteado ⁴, Laura Nuño ⁵, Irene Monjo ⁶, Elisa Fernández ⁷ and Alejandro Balsa ², ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, MADRID, Spain, ⁶FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain
Background/Purpose: Assessment of the disease in psoriatic arthritis (PsA) remains a clinical challenge. Hence, there is no agreement on which index best correlates with the…
Abstract Number: 2484 • 2019 ACR/ARP Annual Meeting
Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia ², Victoria Navarro-Compán ³, Diana Peiteado ⁴, Alejandro Villalba ⁵, Laura Nuño ⁶, Elisa Fernández ⁷ and Alejandro Balsa ², ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, ⁶Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain
Background/Purpose: Gender has been lately suggested as influential in the response to treatment with biological drugs in spondyloarthritis. However, data about the association between gender…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].